An oligonucleotide compound containing a carbon-cyclic nucleoside modification, its pharmaceutical composition, and its uses.
By designing oligonucleotide compounds modified with carbon-cyclic nucleosides, the problem of traditional drugs being unable to effectively reduce AGT levels was solved, achieving the effects of significantly reducing AGT expression and prolonging the duration of drug action.
Patent Information
- Application Number
- CN202410422579.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2024-04-09
- Publication Date
- 2026-11-17
- Estimated Expiration
- 2044-04-09
AI Technical Summary
Existing traditional small molecule drugs cannot effectively reduce angiotensinogen (AGT) levels. Oligonucleotide compounds targeting the AGT gene have shown significant and durable antihypertensive effects in animal models, but their activity, stability, or pharmacokinetic properties still need to be improved.
An oligonucleotide compound modified with a carbocyclic nucleoside was designed, comprising a carbocyclic nucleoside with a specific structure and a 2'-O-methoxyethyl modified nucleoside, which are linked by a thiophosphate ester to target the AGT gene, improve stability and reduce AGT expression.
This oligonucleotide compound significantly reduces AGT expression, has a long retention time in vivo, a long half-life, and a long duration of efficacy, making it suitable for formulation into drugs with longer dosing intervals and better therapeutic value.
Smart Images

Figure CN118324834B_ABST
Abstract
Description
Technical Field
[0001] This invention belongs to the field of pharmaceutical technology, specifically relating to an oligonucleotide compound containing a carbon-cyclic nucleoside modification and its pharmaceutical composition, as well as its use in the preparation of drugs for treating, preventing or alleviating diseases associated with angiotensinogen. Background of the Invention Hypertension is the most prevalent non-infectious chronic disease globally. With factors such as population aging, increasing obesity, increased life stress, and changes in dietary structure, the hypertensive population is growing rapidly. Hypertension is the root cause and trigger of many chronic diseases, and its complications include cerebral thrombosis, coronary heart disease, heart failure, and kidney disease. While significant progress has been made in the diagnosis and treatment of hypertension in recent years, the treatment and control rates remain unsatisfactory. Reasons include medications not meeting patient needs, poor patient adherence, and comorbidities, among which refractory hypertension is a significant component. Refractory hypertension is a special type of hypertension in which patients cannot achieve target blood pressure even with three antihypertensive drugs. Refractory hypertension accounts for approximately 5% to 30% of hypertension patients. These patients experience more significant target organ damage, and their risk of myocardial infarction, stroke, and death is 2 to 6 times higher than that of ordinary hypertensive patients, making its treatment particularly difficult.
[0002] The renin-angiotensin system (RAS) plays a crucial role in the development and progression of cardiovascular diseases such as hypertension, coronary heart disease, and heart failure. Traditional RAS blockers, including angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs), exert target organ protection by blocking different stages of the RAS and are currently first-line drugs in hypertension treatment. Angiotensinogen (AGT) is the only precursor protein of all angiotensin hormones and a rate-limiting substrate of the RAS. Under the action of renin, AGT is converted into angiotensin I (Ang I). Under the catalysis of angiotensin-converting enzyme, Ang I is hydrolyzed to angiotensin II (Ang II). After Ang II binds to its receptor, it can lead to increased vascular resistance, vasoconstriction, increased cardiac output, and promotion of aldosterone release. Aldosterone has the effects of sodium retention and potassium excretion, promoting sodium and water reabsorption, resulting in increased blood volume and elevated blood pressure. Plasma AGT concentration is closely related to blood pressure, and plasma AGT levels in hypertensive individuals and their offspring are significantly higher than in normal individuals. AGT gene molecular variations are associated with hypertension, making AGT a promising target for hypertension treatment. Besides its crucial role in regulating hypertension, AGT also plays a significant role in the development of other diseases. Studies have found that renin-angiotensin activity is significantly upregulated in patients with type 2 diabetes, with higher plasma AGT levels than in controls. AGT gene polymorphisms may be associated with the risk of diabetic nephropathy. Atherosclerosis has been observed in transgenic mice implanted with human angiotensinogen, and the angiotensinogen gene variant M235T has also shown a correlation with atherosclerosis in different populations.
[0003] Traditional small-molecule drugs are ineffective in lowering AGT levels, while oligonucleotide compounds targeting the AGT gene have shown significant and durable antihypertensive effects in animal models. Oligonucleotides are a class of synthetic oligonucleotides with nucleobase sequences that are complementary to target mRNA via Watson-Crick base pairing. Oligonucleotides utilize gene silencing technology to precisely regulate the expression of pathogenic genes, exhibiting strong targeting specificity and significant clinical implications. Unmodified oligonucleotides are readily degraded by nucleases in vivo, exhibiting poor stability. Modification of nucleosides with 2'-OMe, 2'-MOE, or cEt can improve stability, increase affinity, and reduce immunogenicity, thereby enhancing the drug-likeness of oligonucleotides. Patents US10912792B2 and US11447521B2 describe the varying degrees of regulatory effects of oligonucleotides modified with 2'-MOE or cEt on AGT in cell and animal models. Although some progress has been made in oligonucleotides targeting AGT, there is still a need to invent oligonucleotide compounds with further improvements in activity, stability, or pharmacokinetic properties. Summary of the Invention
[0004] In view of the shortcomings of the existing technology, the present invention aims to provide an oligonucleotide containing a carbon-cyclic nucleoside for regulating angiotensinogen expression, a pharmaceutical composition thereof, and its use.
[0005] On one hand, the present invention provides an oligonucleotide compound modified with a carbocyclic nucleoside, said oligonucleotide compound comprising at least one carbocyclic nucleoside of formula (I):
[0006] (I) Wherein, Base is a heterocyclic base, and the heterocyclic base is selected from any one of thymine, 5-methylcytosine, cytosine, adenine, guanine, or uracil, and their structural formulas are as follows:
[0007] Preferably, the oligonucleotide compound is composed of 12 to 24 linked nucleosides, comprising: A gap segment composed of linked deoxynucleosides; The 5' wing segment composed of linked nucleosides; The 3' wing segment composed of linked nucleosides; The gap segment is located between the 5' wing segment and the 3' wing segment, and each nucleoside in each wing segment is a modified nucleoside; The 5' wing region includes 1 to 5 modified nucleosides, and the 3' wing region includes 1 to 5 modified nucleosides.
[0008] Among them, the modified nucleosides include carbocyclic nucleosides of formula (I) and nucleosides modified with 2'-O-methoxyethyl; the linkage between each nucleoside is a thiophosphate linkage; and each cytosine is 5-methylcytosine.
[0009] As some preferred embodiments, the carbon-cyclic nucleoside-modified oligonucleotide compound comprises a compound of the following formula or a pharmaceutically acceptable salt thereof: ; In some other preferred embodiments, the carbon-cyclic nucleoside-modified oligonucleotide compound comprises a compound of the following formula or a pharmaceutically acceptable salt thereof: ; In some other preferred embodiments, the carbon-cyclic nucleoside-modified oligonucleotide compound comprises a compound of the following formula or a pharmaceutically acceptable salt thereof: ; In some other preferred embodiments, the carbon-cyclic nucleoside-modified oligonucleotide compound comprises a compound of the following formula or a pharmaceutically acceptable salt thereof: .
[0010] Preferably, the pharmaceutically acceptable salt of the oligonucleotide compound containing a carbon-cyclic nucleoside modification is a sodium salt, and the pharmaceutically acceptable sodium salt of the oligonucleotide compound containing a carbon-cyclic nucleoside modification is one of the following formulas: , , or .
[0011] On the other hand, the present invention also provides an oligonucleotide pharmaceutical composition containing a carbocyclic nucleoside modified oligonucleotide compound, comprising the above-mentioned carbocyclic nucleoside modified oligonucleotide compound or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or diluent.
[0012] In another aspect, the present invention also provides the use of the above-mentioned oligonucleotide compounds containing carbon-cyclic nucleosides modified with oligonucleotides or pharmaceutically acceptable salts thereof, or pharmaceutical compositions, in the preparation of drugs that reduce AGT mRNA expression.
[0013] In another aspect, the present invention also provides the use of the above-mentioned oligonucleotide compounds containing carbocyclic nucleosides modified with carbonyl cyclic nucleosides or pharmaceutically acceptable salts thereof, or pharmaceutical compositions thereof, in the preparation of medicaments for treating and / or preventing and / or alleviating diseases related to AGT.
[0014] The diseases associated with AGT mentioned above are hypertension, kidney disease, atherosclerosis, or hepatic steatosis.
[0015] Compared with the prior art, the beneficial effects of the present invention are as follows: The carbon-cyclic nucleoside compounds provided by this invention have good stability, significantly reduce AGT expression, and have a long in vivo retention time and half-life. Compared with publicly disclosed compounds, they have greater therapeutic value and can be used to formulate oligonucleotide drugs with long-lasting effects and longer dosing intervals. Attached Figure Description
[0016] Figure 1 The knockout rate of AGT mRNA in IVH-AGT model mice. Detailed Implementation
[0017] It should be understood that the foregoing overview and the following detailed description are merely exemplary and illustrative, and do not limit the embodiments as claimed.
[0018] Unless otherwise specified, the following terms have the following meanings. Any undefined term has the generally accepted meaning in its neighborhood.
[0019] As used in this article, "oligonucleotide" is composed of 12-24 linked nucleosides that are covalently linked by phosphate groups such as phosphate esters, thiophosphate esters, aminoalkyl phosphate triesters, and alkyl phosphate esters to form a linear polymer compound.
[0020] As used herein, a nucleoside is a compound consisting of a ribose (or deoxyribose) and a nucleobase (purine or pyrimidine) linked by a glycosidic bond, and is a basic building block of nucleic acids. Nucleosides include natural nucleosides in the form of 2'-deoxy and 2'-hydroxyl groups, as well as modified nucleosides with modified base moieties and / or modified sugar moieties.
[0021] As used in this article, "deoxynucleoside" refers to a nucleoside containing a 2'-H furanose moiety.
[0022] As used in this article, “linked nucleosides” refers to adjacent nucleosides linked together.
[0023] As used in this article, "base" refers to the common DNA and RNA bases (uracil, thymine, adenine, guanine, and cytosine), as well as modified bases such as 5-methylcytosine.
[0024] As used herein, “2’-O-methoxyethyl” (also known as 2’-MOE, 2’-O(CH2)2-OCH3) refers to the O-methoxy-ethyl modification at the 2’ position of a sugar ring (e.g., a furanose ring). Sugars modified with 2’-O-methoxyethyl are modified sugars.
[0025] As used herein, “cEt” (also known as constrained ethyl) refers to the ribosyl dicyclic sugar moiety, wherein the second ring of the dicyclic sugar is formed via a bridge connecting the 4'-carbon and the 2'-carbon, wherein the bridge has the formula: 4'-CH(CH3)-O-2'.
[0026] As used in this article, “cLNA” refers to a nucleoside containing a carbon ring with the structure of Formula I in this article.
[0027] As used herein, "5-methylcytosine" refers to cytosine modified with a methyl group at the 5' position. 5-methylcytosine is a modified nucleobase.
[0028] As used in this article, "thiophosphate linkage" refers to a modified phosphate linkage in which one of the non-bridging oxygen atoms is replaced by a sulfur atom.
[0029] As used in this article, "pharmaceutically acceptable salt" means a physiologically and pharmaceutically acceptable salt of a compound that retains the desired biological activity of the parent compound and does not impart undesirable toxicological effects.
[0030] As used herein, "pharmaceuticalally acceptable carrier" refers to a medium or diluent that does not interfere with the structure or function of oligonucleotides, an adjunct other than oligonucleotides administered to animals or humans, some of which enable the formulation of pharmaceutical compositions into oral preparations such as tablets, capsules, liquids, suspensions, etc., and some of which enable the formulation of pharmaceutical compositions into injectable or infusion preparations. For example, pharmaceutically acceptable carriers may be sterile aqueous solutions or physiological saline.
[0031] As used herein, "pharmaceutical composition" means a mixture of substances suitable for individual administration. For example, a pharmaceutical composition may comprise one or more compounds or salts thereof and a sterile aqueous solution.
[0032] As used herein, when oligonucleotides are represented by letter sequences such as “CGCTGATTT”, unless otherwise indicated, it should be understood that the nucleotides are in a 5'→3' sequence from left to right, and that “C” represents cytidine, “G” represents guanosine, “T” represents thymidine, “A” represents adenosine, and “U” represents uridine.
[0033] In some embodiments, the carbon-cyclic nucleoside-modified oligonucleotides of the present invention are antisense oligonucleotides, comprising modified oligonucleotides of 16 linked nucleosides targeting AGT.
[0034] The modified oligonucleotide compounds mentioned above include: A gap segment consisting of ten linked deoxynucleotides; The 5' wing segment consists of three linked nucleosides; The 3' wing segment consists of three linked nucleosides; The notched segment is located between the 5' wing segment and the 3' wing segment. Each nucleoside in each wing segment is a modified nucleoside. The modified nucleosides in each wing segment include carbocyclic nucleosides of Formula I and nucleosides modified with 2'-O-methoxyethyl. The linkages between each nucleoside are thiophosphate linkages. Each cytosine is 5-methylcytosine.
[0035] In some embodiments, the carbon-cyclic nucleoside-modified oligonucleotides of the present invention are antisense oligonucleotides, comprising modified oligonucleotides of 20 linked nucleosides targeting AGT.
[0036] The modified oligonucleotide compounds mentioned above include: A gap segment consisting of ten linked deoxynucleotides; The 5' wing segment consists of five linked nucleotides; The 3' wing segment consists of five linked nucleotides; The notched segment is located between the 5' wing segment and the 3' wing segment. Each nucleoside in each wing segment is a modified nucleoside. The modified nucleosides in each wing segment include carbocyclic nucleosides of Formula I and nucleosides modified with 2'-O-methoxyethyl. The linkages between each nucleoside are thiophosphate linkages. Each cytosine is 5-methylcytosine.
[0037] In some embodiments, the carbon-cyclic nucleoside-modified oligonucleotide comprises or consists of compound 1 or a salt thereof, and the structural formula of compound 1 is shown in Formula 1 below: (1) In some embodiments, the carbon-cyclic nucleoside oligonucleotide comprises or consists of compound 2 or a salt thereof, and the structural formula of compound 2 is shown in Formula 2 below: (2) In some embodiments, the oligonucleotide containing a carbon-cyclic nucleoside comprises compound 3 or a salt thereof, or is composed of the like, and the structural formula of compound 3 is shown in Formula 3 below: (3) In some embodiments, the carbon-cyclic nucleoside oligonucleotide comprises or consists of compound 4 or a salt thereof, and the structural formula of compound 4 is shown in Formula 4 below: (4) The oligonucleotides or pharmaceutical compositions thereof modified with carbon-cyclic nucleosides described in this invention have in vitro IC50 values of less than 7 nM, less than 5 nM, and less than 3 nM. 50 It is one of the active ones.
[0042] The oligonucleotides or pharmaceutical compositions thereof modified with carbon-cyclic nucleosides described in this invention are active and have a knockout rate of more than 70%, more than 80%, or more than 90% in model mice over 7 days.
[0043] The following examples illustrate in more detail the synthesis, in vivo and in vitro biological properties, and physicochemical stability of the carbon-containing cyclic nucleoside oligonucleotides for regulating AGT expression according to the present invention. However, the following examples are only for illustrating the compounds described herein and are not intended to limit the present invention.
[0044] Example 1: Synthesis of C-cyclic nucleoside phosphoramidide monomer G
[0045] (1) Synthesis of compound G-5
[0046] Under a nitrogen atmosphere, compound G-4 (575 g, 2 mol) (synthesis reference: Journal of Medicinal Chemistry, 2014, vol. 57, # 5, p. 2107 - 2120) was dissolved in 10 L of dichloromethane. The solution was cooled to -20 to -25 °C, and 5 L of 0.4 M sodium methoxide methanol solution was slowly added dropwise. After the addition was complete, stirring was continued for 30 min. After detection by thin-layer chromatography, the reaction was quenched dropwise with 4 M HCl 1,4-dioxane solution, and the pH was adjusted to <7. The solution was filtered, concentrated, and the crude product was purified by column chromatography using petroleum ether:ethyl acetate = 5:1 to 3:1 as the eluent, yielding 228 g of oily substance, with a yield of 80%. [M+1] + =143.1; 1H NMR (400 MHz, Chloroform-d) δ 5.98 – 5.87 (m, 1H), 5.76 (dq, J = 5.9, 2.1 Hz, 1H), 5.12 (dp, J = 5.6, 1.8 Hz, 1H), 3.75 (s, 3H), 2.96 (ddd, J = 9.0, 6.7,5.2 Hz, 1H), 2.78 (ddq, J = 15.9, 9.0, 2.3 Hz, 1H), 2.66 – 2.55 (m, 1H).
[0047] (2) Synthesis of compound G-6
[0048] Under a nitrogen atmosphere, compound G-5 (50 g, 0.352 mol) was dissolved in 500 mL of dry tetrahydrofuran and 170 mL of hexamethylphosphoric triamine. The mixture was cooled to -78 °C, and 530 mL of 2 M diisopropylaminolithium in tetrahydrofuran was slowly added dropwise. After the addition was complete, the temperature was raised to -20 °C and stirring was continued for 30–45 min. Then, the temperature was lowered to -78 °C, and a dry tetrahydrofuran solution of benzylchloromethyl ether (66 g, 0.422 mol) was slowly added dropwise. After the addition was complete, the temperature was slowly raised to -40 °C and the reaction was carried out for 2 h. After the reaction was detected by gas chromatography, acetic acid was added dropwise to quench the reaction, the temperature was raised to room temperature, a saturated ammonium chloride solution was added, and the mixture was extracted twice with ethyl acetate. The combined organic phases were washed successively with saturated brine, dried over anhydrous sodium sulfate, filtered, and concentrated. The crude product was purified by column chromatography using petroleum ether:ethyl acetate as the eluent in a ratio of 5:1 to 4:1, yielding 63 g of oily product in 68% yield. [M+1] +=263.2; 1H NMR (400MHz, Chloroform-d) δ 7.40 – 7.29 (m, 5H), 5.99 (dt, J = 5.3, 2.3 Hz, 1H), 5.76 (dq, J = 6.8, 2.2 Hz, 1H), 4.57 (d, J = 2.3 Hz, 1H), 4.54 (s, 2H), 3.79(d, J = 8.7 Hz, 1H), 3.77 (s, 3H), 3.39 (d, J = 8.7 Hz, 1H), 3.12 (dt, J =17.8, 2.4 Hz, 1H), 2.55 (dt, J = 17.8, 2.3 Hz, 1H).
[0049] (3) Synthesis of compound G-7
[0050] Under a nitrogen atmosphere, compound G-6 (63 g, 0.24 mol) was dissolved in 600 mL of dichloromethane. The solution was cooled to 0 °C, and 121.8 g (0.6 mol) of 85% m-chloroperoxybenzoic acid was added in portions. The mixture was stirred overnight at room temperature. After the reaction was complete as detected by LCMS, the reaction was quenched with saturated sodium sulfite solution. The organic phase was then washed successively with saturated sodium bicarbonate solution, dried over anhydrous sodium sulfate, filtered, and concentrated. The crude product was purified by column chromatography using petroleum ether:ethyl acetate (5:1–4:1) as the eluent, yielding 45 g of oily product in 67% yield. [M+1] + =288.1.
[0051] (4) Synthesis of compound G-8
[0052] Under a nitrogen atmosphere, compound G-7 (35.2 g, 0.126 mol) was dissolved in 250 mL of dry N,N-dimethylformamide, and benzyl bromide (32.3 g, 0.189 mol) was added. The mixture was cooled to -40 to -50 °C, and 189 mL of 1 M bis(trimethylsilyl)amino potassium in tetrahydrofuran solution was slowly added dropwise. After the addition was complete, the reaction was continued for 1 h. After the reaction was detected by LCMS, acetic acid was added to quench the reaction, and the mixture was heated to room temperature. Saturated ammonium chloride solution was added, and the mixture was extracted twice with ethyl acetate. The organic phases were combined, washed twice with saturated brine, dried over anhydrous sodium sulfate, filtered, and concentrated. The crude product was purified by column chromatography with petroleum ether:ethyl acetate as the eluent in a ratio of 5:1 to 4:1, yielding 40 g of oily product in 84% yield. [M+1] + =369.2.
[0053] (5) Synthesis of compound G-9
[0054] Under a nitrogen atmosphere, compound G-8 (39 g, 0.106 mol) was dissolved in 1.2 L of dry dichloromethane. The solution was cooled to -78 °C, and 254 mL of a 1 M diisobutylaluminum hydride solution in n-hexane was slowly added dropwise. After the addition was complete, the reaction was continued at -78 °C for 1 h. The reaction was monitored by LC-MS until complete. Acetic acid was added to quench the reaction, and the temperature was raised to room temperature. The organic phase was washed successively with saturated sodium bicarbonate aqueous solution, saturated brine, and dried over anhydrous sodium sulfate. The solution was filtered and concentrated. The crude product was purified by column chromatography using petroleum ether:ethyl acetate = 4:1 as the eluent, yielding 28 g of oil (77.7%). [M+1] + =341.2; 1H NMR (400 MHz, Chloroform-d) δ 7.41 – 7.29 (m, 7H), 4.80 (d, J = 11.9 Hz, 1H), 4.60 (d, J = 11.9 Hz, 1H), 4.47 (q, J = 12.1 Hz, 2H), 4.20 (s, 1H), 3.87 (d, J = 11.2 Hz, 1H), 3.60(d, J = 2.7 Hz, 1H), 3.47 (d, J = 8.3 Hz, 3H), 3.37 (d, J = 9.1 Hz, 1H), 2.98(s, 1H), 2.05 – 1.99 (m, 1H), 1.92 (d, J = 14.9 Hz, 1H).
[0055] (6) Synthesis of compound G-10
[0056] Under a nitrogen atmosphere, compound G-9 (24 g, 0.07 mol), cesium fluoride (31.9 g, 0.21 mol), and O-6-benzylguanine (33.8 g, 0.14 mol) were suspended in 240 mL of dry DMF. The mixture was heated to 90 °C and reacted for 3 h. The reaction was monitored by LCMS until completion. The mixture was then cooled, water was added, and the mixture was extracted twice with ethyl acetate. The organic phases were combined, washed twice with saturated brine, dried over anhydrous sodium sulfate, filtered, and concentrated. The crude product was purified by column chromatography using petroleum ether:ethyl acetate as the eluent in a ratio of 1:2 to 1:3, yielding 23.3 g of oily product, with a yield of 56.8%. [M+1] +=582.2; 1H NMR (400 MHz, Chloroform-d) δ 7.64 (s, 1H), 7.57-7.47 (m, 2H), 7.46-7.29 (m, 13H), 5.58 (s, 2H), 4.94 (d, J = 11.4 Hz, 1H), 4.88 (s, 2H), 4.70 (dd, J = 10.8, 3.0 Hz, 2H), 4.57 (dd, J = 8.4, 5.6 Hz, 1H), 4.52 (s, 2H), 4.15 (d, J = 5.6 Hz, 1H), 3.85 (d, J = 11.3 Hz, 1H), 3.66(d, J = 11.3 Hz, 1H), 3.41 (s, 2H), 2.38 (dd, J = 13.3, 8.7 Hz, 1H), 2.09 -1.96 (m, 2H).
[0057] (7) Synthesis of compound G-11
[0058] Under a nitrogen atmosphere, compound G-10 (23.2 g, 0.04 mol) was dissolved in 230 mL of dry pyridine. The solution was cooled to 0 °C, and trimethylchlorosilane (26.1 g, 0.24 mol) was slowly added dropwise. After the addition was complete, the solution was stirred at room temperature for 2 h. The solution was then cooled to 0 °C, and isobutyryl chloride (4.7 g, 0.044 mol) was slowly added dropwise. After the addition was complete, the solution was stirred for another 2 h. 30 mL of concentrated ammonia was added dropwise, and the solution was stirred at room temperature for 1 h. The reaction was monitored by LCMS until completion. Water was added, and the solution was extracted twice with ethyl acetate. The organic phases were combined, washed twice with saturated brine, dried over anhydrous sodium sulfate, filtered, and concentrated. The crude product was purified by column chromatography using petroleum ether:ethyl acetate as the eluent, yielding 26.3 g of an oily liquid, with a yield of 97%. [M+1] + =652.3.
[0059] (8) Synthesis of compound G-12
[0060] Under a nitrogen atmosphere, compound G-11 (25.5 g, 0.039 mol) was dissolved in 200 mL of dry pyridine. The solution was cooled to 0 °C, and a tetrahydrofuran solution of methanesulfonic anhydride (8.7 g, 0.051 mol) was slowly added dropwise. After the addition was complete, stirring was continued for 2 h. The reaction was monitored by LCMS until the product concentration reached its maximum. Water was added to quench the reaction, and the product was extracted twice with ethyl acetate. The combined organic phases were washed twice with saturated brine, dried over anhydrous sodium sulfate, filtered, and concentrated. The crude product was purified by column chromatography using petroleum ether:ethyl acetate (1:1) as the eluent, yielding 19.1 g of oil (56.8%). 4.5 g of the starting material was recovered. [M+1] + =730.3.
[0061] (9) Synthesis of compound G-13
[0062] Under a nitrogen atmosphere, 3.5 g (87.9 mmol) of 60% sodium hydride was carefully added to 210 mL of dry N,N-dimethylformamide, and stirred for 10 min. The mixture was cooled to 0 °C, and a solution of compound G-12 (21.4 g, 29.3 mmol) in N,N-dimethylformamide was slowly added dropwise. After the addition was complete, stirring was continued for 2 h. The reaction was monitored by LCMS until complete. The reaction was quenched with acetic acid, and the mixture was extracted twice with ethyl acetate after adding saturated sodium bicarbonate solution. The combined organic phases were washed successively with saturated brine, dried over anhydrous sodium sulfate, filtered, and concentrated. The crude product was purified by column chromatography using petroleum ether:ethyl acetate (1:1) as the eluent, yielding 15.8 g of an oily substance in 85% yield. [M+1] + =634.3.
[0063] (10) Synthesis of compound G-14
[0064] Under a nitrogen atmosphere, compound G-13 (5 g, 7.9 mmol) was dissolved in 50 mL of a 9:1 mixture of ethanol and water. 10 mL of formic acid and 5 g of 10% Pd / C were added, and the mixture was heated to 60 °C and reacted for 3 h. The reaction was monitored by LC-MS until completion. The mixture was filtered, and the residue was washed twice with a 9:1 mixture of ethanol and water. The filtrate was concentrated. The crude product was purified by column chromatography using dichloromethane:ethanol (10:1) as the eluent, yielding 2.5 g of a white solid, with a yield of 87.2%. [M+1] += 364.1; 1H NMR (400 MHz, DMSO-d6) δ 8.14 (s,1H), 7.36 – 7.21 (m, 1H), 5.17 (d, J = 4.2 Hz, 1H), 4.59 (t, J = 5.2 Hz, 1H), 4.44 (dd, J = 9.7, 5.4 Hz, 1H), 4.03 (d, J = 4.4 Hz, 1H), 3.96 (s, 1H), 3.78– 3.68 (m, 2H), 2.79 (p, J = 6.8 Hz, 1H), 2.23 (ddd, J = 26.1, 14.8, 10.2 Hz,2H), 1.99 (dd, J = 10.2, 6.6 Hz, 1H), 1.12 (d, J = 6.8 Hz, 5H).
[0065] (11) Synthesis of compound G-15
[0066] Under a nitrogen atmosphere, compound G-14 (3.1 g, 9.1 mmol) and 4,4'-dimethoxytriphenylmethyl chloride (6.8 g, 20.2 mmol) were dissolved in 30 mL of dry dichloromethane. The solution was cooled to 0 °C, and N,N-diisopropylethylamine (5.89 g, 45.5 mmol) was slowly added dropwise. After the addition was complete, the solution was heated to room temperature and stirred for 2 h. The reaction was monitored by LCMS until completion. The solution was concentrated, and the crude product was purified by column chromatography using dichloromethane:methanol:triethylamine = 30:1:0.1% as the eluent, yielding 4.6 g of a pale yellow solid, with a yield of 76%. [M+1] +=666.3; 1H NMR (400 MHz, Chloroform-d) δ 12.10 (s, 1H), 9.40 (s, 1H), 7.75 (s,1H), 7.46 – 7.40 (m, 2H), 7.34 – 7.25 (m, 5H), 7.23 – 7.17 (m, 2H), 6.83(ddd, J = 9.0, 4.2, 2.0 Hz, 4H), 4.66 (s, 1H), 4.48 (t, J = 7.6 Hz, 1H), 4.27(s, 1H), 3.95 (d, J = 7.1 Hz, 1H), 3.82 (s, 1H), 3.78 (s, 6H), 3.68 (d, J =7.0 Hz, 1H), 3.46 (d, J = 9.6 Hz, 1H), 3.27 (d, J = 9.6 Hz, 1H), 2.53 (p, J =6.9 Hz, 1H), 2.32 (d, J = 7.6 Hz, 2H), 1.19 (dd, J = 9.7, 6.8 Hz, 6H).
[0067] (12) Synthesis of compound G
[0068] Under a nitrogen atmosphere, compound G-15 (1.0 g, 1.5 mmol) and 4,5-dicyanimidazole (443 mg, 3.75 mmol) were dissolved in 10 mL of dry dichloromethane. Bis(diisopropylamino)(2-cyanoethoxy)phosphine (1.1 g, 3.75 mmol) was added dropwise at room temperature, and stirring was continued for 2 h. After the reaction was monitored by LCMS, dichloromethane and 0.1 mL of triethylamine were added. The organic phase was washed sequentially with saturated brine, dried over anhydrous sodium sulfate, filtered, and concentrated. The crude product was separated using preparative high-performance liquid chromatography (HPLC) on a C18 column with a mobile phase of acetonitrile (containing 0.0035% diisopropylamine):water (containing 0.0035% diisopropylamine) = 7:3, yielding 660 mg of a white solid, in 51% yield. [M+1] + =866.4; 31 PNMR: 147.27, 147.17.
[0069] Example 2: Synthesis and purification of oligonucleotide compounds 1-4 modified with carbon-cyclic nucleosides Oligonucleotide analogs containing the carbocyclic nucleoside phosphoramide monomer G from Example 1 were synthesized in a multi-step solid-phase process using an automated oligonucleotide synthesizer and a solid-phase support with phosphoramide nucleoside monomers at a rate of 0.2 μmol. The resulting compounds were compounds 1, 2, 3, and 4, with sequences and modifications shown in Table 1. The coupling time between the carbocyclic nucleoside phosphoramide monomer G (compound G) and the 5'-terminal hydroxyl group was 15 min, the MOE phosphoramide monomer coupling time was 10 min, and the typical DNA phosphoramide monomer coupling time was 8 min.
[0070] The crude oligonucleotide analogue was purified by ion-pair reversed-phase liquid chromatography using a NanoQ-15L 9.5ml (8X190 mm) ion exchange column at a flow rate of 2ml / min. The mobile phase A was 10mM sodium hydroxide solution, and the mobile phase B was 10mM sodium hydroxide and 2.0M sodium chloride solution. Gradient elution was performed to obtain oligonucleotide compounds with the required purity.
[0071] Table 1. Several oligonucleotide compounds targeting human AGT with MOE, cEt, and cLNA modifications.
[0072] Modification explanation: "d" indicates deoxyribose; "e" indicates MOE modification; "k" indicates cEt modification; "c" indicates cLNA modification.
[0073] Example 3: Inhibitory effect of carbon-cyclic nucleoside-modified oligonucleotides on human angiotensinogen (AGT) in Huh7 cells. Antisense oligonucleotide compounds 1-4 targeting human AGT were designed with C-cyclic nucleoside modifications, as shown in Table 1 of Example 2. Their effects on AGT mRNA in vitro were tested. Each oligonucleotide was diluted to concentrations of 1.563 nM, 6.25 nM, 25 nM, and 100 nM as shown in Table 2, and mixed with an equal volume of RNAiMAX. After incubation at room temperature for 15 min, the transfected oligonucleotides were mixed with Huh7 cell suspension at a concentration of 20,000 cells per well. Cells were cultured at 37°C and 5% CO2 for 48 h. Cells were then collected, and RNA was extracted from the cells. The expression level of AGT mRNA was measured by quantitative real-time PCR.
[0074] The results are shown in Table 2 below, displaying the inhibition rate and the half-maximal inhibitory concentration (IC50) of each oligonucleotide. 50 Inhibition rate % = (1 – relative expression level of sample / average expression level of control) 100. In treated cells, the inhibitory rate of antisense oligonucleotides on AGT mRNA increased in a dose-dependent manner, and the IC50 of each antisense oligonucleotide was [not specified]. 50 All are at the low nM level.
[0075] Table 2. Inhibition of AGT mRNA by oligonucleotide compounds
[0076] Example 4: Inhibitory effect of C-cyclic nucleoside modified oligonucleotides on AGT mRNA in IVH-AGT model mice IVH-AGT model mice containing humanized AGT were used, with 3 mice in each group. Each group received a single subcutaneous injection of the oligonucleotide compound listed in Table 1 of Example 2. The dose was 25 mg / kg. Seven days later, the mice were sacrificed, and liver tissue was collected. Total RNA was extracted, and the expression of human AGT mRNA was detected by quantitative real-time PCR. Mice injected with PBS served as a negative control group, and the oligonucleotide injection group was compared with this group. The knockout rate was calculated using a normalization method, as shown in the formula below:
[0077] The results are shown below. Figure 1 In IVH-AGT model mice, the knockout rate exceeded 70% after 7 days of oligonucleotide injection, and AGT mRNA expression was significantly reduced.
[0078] Example 5: Stability of oligonucleotide compounds modified with carbon-cyclic nucleosides to exonucleases The stability of the oligonucleotide compounds in Table 1 of Example 2 above against exonucleases that break down from the 3' side was investigated. A buffer solution (65 µL) containing 750 pmol of oligonucleotide was incubated at 37°C for 5 minutes, followed by a 35 µL buffer solution containing 5 µg / mL snake venom phosphodiesterase (Crotalus admanteus venom phosphodiesterase (CAVP): Merck KGaA, Darmstadt, Germany). The breakdown of the oligonucleotide was determined over time by HPLC (Thermo UltiMate 3000, analytical column: Waters XBridge™ Shield RP18 3.5 µm (4.6 mm × 150 mm)). The buffer composition (final concentration) used was 50 mM TrisHCl (pH 8.0) and 10 mM MgCl2, and was thoroughly degassed before analysis. The HPLC quantitative conditions are shown below.
[0079] HPLC quantification conditions: Mobile phase: Solution A, 0.1M triethylacetate ammonium buffer, pH 7.0 Solution B: 0.1M triethylacetate ammonium buffer: acetonitrile = 1:1 (v / v), pH 7.0 Gradient: 15→40% (v / v) Solution B (7 minutes) Column used: Waters XBridge™ Shield RP18 3.5 µm (4.6 mm × 150 mm) Flow rate: 1.0 mL / min Column temperature: 50℃ Detection: UV (268 nm) The results are shown in Table 3, which shows the retention rates of each oligonucleotide compound at different time points within 24 hours of nuclease treatment. The oligonucleotides showed good stability to exonuclease.
[0080] Table 3. 24-hour retention rate of oligonucleotide compounds against exonucleases.
[0081] Example 6: Pharmacokinetics of oligonucleotide compounds modified with carbon-cyclic nucleosides in BALB / c mice In Example 2, the oligonucleotide compound 4 described in Table 1 was dissolved in physiological saline to prepare a 2.5 mg / ml solution. BALB / c mice were administered the solution via tail vein injection at a dose of 25 mg / kg. Plasma was collected within 48 hours after administration, and the supernatant was collected by centrifugation and stored at -80℃. The blood drug concentration was detected by HPLC-MS and analyzed using the statistical moment method. The results are shown in Table 4, indicating that the oligonucleotide containing carbon-cyclic nucleosides has a large distribution volume, significantly longer retention time, and a much longer half-life.
[0082] Table 4. Pharmacokinetic parameters of oligonucleotide compounds in mice after a single dose.
[0083] Example 7: Pharmacokinetics of oligonucleotide compounds modified with carbon-cyclic nucleosides in CD-1 mice In Example 2, several oligonucleotide compounds described in Table 1 were dissolved in physiological saline to prepare a 2.5 mg / ml solution. CD-1 mice were administered the solution via tail vein injection at a dose of 25 mg / kg. Plasma was collected within 48 hours after administration, and the supernatant was collected by centrifugation and stored at -60℃ to -90℃. The blood drug concentration was detected by LC-MS / MS and analyzed using the statistical moment method. The results are shown in Table 5, indicating that the retention times and half-lives of different oligonucleotides containing carbon-cyclic nucleosides were similar.
[0084] Table 5 Pharmacokinetic parameters of oligonucleotide compounds in mice after a single dose.
[0085] Example 8: Pharmacokinetics of oligonucleotide compounds modified with carbon-cyclic nucleosides in cynomolgus monkeys In Example 2, oligonucleotide compounds 1-2 described in Table 1 were dissolved in physiological saline to prepare a 2.5 mg / ml solution. Cynomolgus monkeys were administered the solution via single intravenous and subcutaneous injection at a dose of 5 mg / kg. Plasma was collected within 168 hours after administration, and the supernatant was collected by centrifugation and stored at -60℃ to -90℃. Blood drug concentrations were detected by LC-MS / MS and analyzed using the statistical moment method. The results are shown in Table 6, indicating that the retention times and half-lives of different oligonucleotides containing carbon-cyclic nucleosides were similar.
[0086] Table 6. Pharmacokinetic parameters of oligonucleotide compounds after a single dose to cynomolgus monkeys.
[0087] Obviously, the above embodiments are merely illustrative examples for clear explanation and are not intended to limit the implementation. Those skilled in the art will recognize that other variations or modifications can be made based on the above description. It is neither necessary nor possible to exhaustively list all possible implementations here. However, obvious variations or modifications derived therefrom are still within the scope of protection of this invention.
Claims
1. An oligonucleotide compound containing a carbon-cyclic nucleoside modification, characterized in that: The aforementioned carbon-cyclic nucleoside-modified oligonucleotide compounds comprise one of the following formulas or a pharmaceutically acceptable salt thereof: 、 、 or 。 2. The oligonucleotide compound according to claim 1, characterized in that: The pharmaceutically acceptable salt of the aforementioned carbon-cyclic nucleoside-modified oligonucleotide compound is a sodium salt, and the sodium salt is one of the following compounds: 、 、 or .
3. A oligonucleotide pharmaceutical composition containing carbon-cyclic nucleoside modification, characterized in that: The oligonucleotide pharmaceutical composition comprises the carbon-cyclic nucleoside-modified oligonucleotide compound of claim 1 or 2 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or diluent.
4. The use of the oligonucleotide compound modified with a carbon-cyclic nucleoside as described in claim 1 or 2, or a pharmaceutically acceptable salt thereof, or the oligonucleotide pharmaceutical composition as described in claim 3, in the preparation of a drug for reducing AGT mRNA expression.
5. The use of the carbon-cyclic nucleoside-modified oligonucleotide compound of claim 1 or 2 or its pharmaceutically acceptable salt, or the oligonucleotide pharmaceutical composition of claim 3, in the preparation of a medicament for the treatment and / or prevention and / or relief of AGT-related diseases.
6. The application according to claim 5, characterized in that: The diseases associated with AGT mentioned above are hypertension, kidney disease, atherosclerosis, or hepatic steatosis.
Citation Information
Patent Citations
Compounds and methods for modulating angiotensinogen expression
US10912792B2
Compounds and methods for modulating angiotensinogen expression
US11447521B2
